GYRE
GYRE THERAPEUTICS, INC.
Latest Form 4:Sale$107KbyYe Weiguo (Chief Operating Officer) · filed Jun 22, 2026
GYRE THERAPEUTICS, INC. (GYRE) has 9 SEC Form 4 filings (34 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jun 22, 2026.
The most active filer is Chief Operating Officer Ye Weiguo with 14 filings. Insiders have net sold $953K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Ping Zhang
- Employees:579
- HQ:San Diego, CA, US
- IPO:2006-04-12
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$953K
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$734.8M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Operating Officer | Sale | 17,500 | $107K | Jun 22 | SEC ↗ | |
| Chief Operating Officer | Sale | 11,418 | $71K | Jun 22 | SEC ↗ | |
| Chief Operating Officer | Sale | 3,000 | $19K | Jun 22 | SEC ↗ | |
| Chief Operating Officer | Sale | 2,800 | $17K | Jun 15 | SEC ↗ | |
| Chief Operating Officer | Sale | 19,575 | $120K | Jun 8 | SEC ↗ | |
| Chief Operating Officer | Sale | 15,401 | $99K | Jun 8 | SEC ↗ | |
| Chief Operating Officer | Sale | 3,500 | $21K | May 27 | SEC ↗ | |
| Chief Operating Officer | Sale | 4,000 | $24K | May 27 | SEC ↗ | |
| Chief Operating Officer | Sale | 9,400 | $58K | May 22 | SEC ↗ | |
| Chief Operating Officer | Sale | 12,820 | $79K | May 22 | SEC ↗ | |
| Chief Operating Officer | Sale | 200 | $1K | May 20 | SEC ↗ | |
| Chief Operating Officer | Sale | 9,120 | $58K | May 20 | SEC ↗ | |
Ye WeiguoFirst filing | Chief Operating Officer | Sale | 15,580 | $108K | May 18 | SEC ↗ |
Ye WeiguoFirst filing | Chief Operating Officer | Sale | 13,100 | $87K | May 18 | SEC ↗ |
Luo YingFirst filing | Chief Executive Officer | Sale | 179 | $1K | May 8 | SEC ↗ |
Luo YingFirst filing | Chief Executive Officer | Sale | 10,136 | $81K | May 8 | SEC ↗ |
Related companies
GYRE THERAPEUTICS, INC. is in the Healthcare sector.